Effect of Epidermal Growth Factor on HLA Class I and II in Breast Cancer Cells
Author Information
Author(s): D.J. Bernard, F. Courjal, J.C. Maurizis, Y.J. Bignon, Ph. Chollet, R. Plagnel
Primary Institution: Unite de Prevention et de Depistage des Cancers, Laboratoire d'Oncologie Molculaire, Centre Jean Perrin
Hypothesis
Does epidermal growth factor (EGF) affect the expression of HLA class I and class II molecules in human breast adenocarcinoma cell lines?
Conclusion
EGF treatment significantly increases the expression of HLA class I and class II antigens in breast cancer cell lines MCF7 and T47D.
Supporting Evidence
- EGF treatment increased HLA class I antigen expression by 7-fold in MCF7 cells.
- EGF treatment increased HLA class II antigen expression by 10-fold in MCF7 cells.
- T47D cells showed a 3-fold increase in HLA class I and a 4-fold increase in HLA class II after EGF treatment.
- RNA levels of HLA class I and class II were not significantly increased in T47D cells after EGF treatment.
Takeaway
This study found that a substance called EGF makes certain proteins on breast cancer cells more visible, which might help the immune system recognize and fight the cancer.
Methodology
The study used Northern blot analysis and immunoprecipitation to assess RNA and protein expression of HLA class I and II in breast cancer cell lines before and after EGF treatment.
Limitations
The study focused only on two specific breast cancer cell lines and may not represent all breast cancer types.
Participant Demographics
The study involved human breast adenocarcinoma cell lines derived from metastatic breast carcinomas.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website